

## Claims

1. An in vitro method for producing activated antigen-specific CD8+cytotoxic T lymphocytes, comprising contacting in vitro T cells with antigen loaded human HLA-A\*02 expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide consisting of the amino acid sequence of YIYKDTIQV (SEQ ID NO: 30).
2. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of YIYKDTIQV (SEQ ID NO: 30) in the form of a pharmaceutically acceptable salt and an immune-stimulating adjuvant.
3. The pharmaceutical composition of claim 2, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
4. The pharmaceutical composition of claim 3, wherein the adjuvant comprises IL-15.
5. The pharmaceutical composition of claim 3, wherein the adjuvant comprises IL-21.
6. An expression vector expressing a nucleic acid encoding a peptide consisting of the amino acid sequence of YIYKDTIQV (SEQ ID NO: 30).
7. A recombinant host cell comprising the expression vector of claim 6, wherein said host cell is a dendritic cell or a macrophage.
8. A method for producing a peptide consisting of the amino acid sequence of YIYKDTIQV (SEQ ID NO: 30), comprising culturing the host cell of claim 7, and isolating the peptide from the host cell or its culture medium.